About: Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials
Creator	Annane, Djillali Murthy, Srinivas Webb, Steve Horby, Peter Perner, Anders Villar, Jesús Gordon, Anthony Marshall, John Angus, Derek Azevedo, Pontes Cesar, Luciano Diaz, Janet Slutsky, Arthur Sterne, Jonathan Green, Cameron Higgins, Julian Lapadula, Giuseppe Tomazini, Bruno Venkatesh, Balasubramanian Jüni, Peter Landray, Martin Dequin, Pierre-Francois Le Gouge, Amelie Leclerc, Marie Savović, Jelena
source	Medline; PMC
abstract	OBJECTIVES: Primary objective: To estimate the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization. Secondary objectives: To examine whether the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization varies between subgroups related to treatment characteristics, disease severity at the time of randomization, patient characteristics, or risk of bias. To examine the effect of corticosteroids compared with usual care or placebo on serious adverse events. STUDY DESIGN: Prospective meta-analysis of randomized controlled trials. Both placebo-controlled and open-label trials are eligible. PARTICIPANTS: Hospitalised, critically ill patients with suspected or confirmed COVID-19. INTERVENTION AND COMPARATOR: Intervention groups will have received therapeutic doses of a steroid (dexamethasone, hydrocortisone or methylprednisolone) with IV or oral administration immediately after randomization. The comparator groups will have received standard of care or usual care or placebo. MAIN OUTCOME: All-cause mortality up to 28 days after randomization. SEARCH METHODS: Systematic searching of clinicaltrials.gov, EudraCT, the WHO ISRCTN registry, and the Chinese clinical trials registry. Additionally, research and WHO networks will be asked for relevant trials. RISK OF BIAS ASSESSMENTS: These will be based on the Cochrane RoB 2 tool, and will use structured information provided by the trial investigators on a form designed for this prospective meta-analysis. SUMMARY OF FINDINGS: We will use GRADE to assess the certainty of the evidence. STATISTICAL ANALYSES: Trial investigators will provide data on the numbers of participants who did and did not experience each outcome according to intervention group, overall and in specified subgroups. We will conduct fixed-effect (primary analysis) and random-effects (Paule-Mandel estimate of heterogeneity and Hartung-Knapp adjustment) meta-analyses. We will quantify inconsistency in effects between trials using I(2) statistics. Evidence for subgroup effects will be quantified by ratios of odds ratios comparing effects in the subgroups, and corresponding interaction p-values. Comparisons between subgroups defined by trial characteristics will be made using random-effects meta-regression. Comparisons between subgroups defined by patient characteristics will be made by estimating trial-specific ratios of odds ratios comparing intervention effects between subgroups then combining these using random-effects meta-analysis. Steroid interventions will be classified as high or low dose according to whether the dose is greater or less than or equal to 400 mg hydrocortisone per day or equivalent. We will use network meta-analysis methods to make comparisons between the effects of high and low dose steroid interventions (because one trial randomized participants to both low and high dose steroid arms). PROSPERO REGISTRATION NUMBER: CRD42020197242 FULL PROTOCOL: The full protocol for this prospective meta-analysis is attached as an additional file, accessible from the Trials website (Additional file 1). To expedite dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol for the systematic review.
has issue date	2020-08-24(xsd:dateTime)
bibo:doi	10.1186/s13063-020-04641-3
bibo:pmid	32831155
has license	cc-by
sha1sum (hex)	673706ed215388538a52e56f620d3fb880a5c02a
schema:url	https://doi.org/10.1186/s13063-020-04641-3
resource representing a document's title	Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials
has PubMed Central identifier	PMC7443535
has PubMed identifier	32831155
schema:publication	Trials
resource representing a document's body	covid:673706ed215388538a52e56f620d3fb880a5c02a#body_text
is schema:about of	named entity 'bias' named entity 'compared' named entity 'randomization' named entity 'subgroups' named entity 'randomization' named entity 'placebo' named entity 'patients' named entity 'structured' named entity 'critically ill' named entity 'UP TO' named entity 'PRIMARY OBJECTIVE' named entity 'OBJECTIVES' named entity 'RISK OF BIAS' named entity 'ALL-CAUSE MORTALITY' named entity 'PARTICIPANTS' named entity 'Participants' named entity 'Both' named entity 'patient' named entity 'mortality' named entity 'corticosteroids' named entity 'days' named entity 'oral administration' named entity 'pharmaceutical company' named entity 'Dexamethasone' named entity 'systematic review' named entity 'Dexamethasone' named entity 'World Health Organisation' named entity 'CIFMS' named entity 'Astra Zeneca' named entity 'Systematic Review' named entity 'French Ministry of Health' named entity 'St. Jude Medical' named entity 'GRADE' named entity 'clinical trial' named entity 'principal investigator' named entity 'groups' named entity 'methylprednisolone' named entity 'steroid' named entity 'varies' named entity 'doses' named entity 'placebo' named entity 'corticosteroids' named entity 'comparator' named entity 'critically ill patients' named entity '28 days' named entity 'randomization' named entity 'meta-analysis' named entity 'care' named entity 'STEROID trial' named entity 'dexamethasone' named entity 'COVID-19' named entity 'France' named entity 'ethics' named entity 'Amgen' named entity 'CIHR' named entity 'EudraCT' named entity 'Srinivas Murthy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software